Advertisement
U.S. markets open in 3 hours 35 minutes
Advertisement

Lipocine Inc. (LPCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.4000-0.1400 (-5.51%)
At close: 04:00PM EST
2.5600 +0.16 (+6.67%)
After hours: 07:29PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Performance Outlook
Previous Close2.5400
Open2.5000
Bid0.0000 x 900
Ask0.0000 x 1100
Day's Range2.4000 - 2.5328
52 Week Range2.3100 - 10.3360
Volume10,521
Avg. Volume18,685
Market Cap12.758M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-3.2100
Earnings DateNov 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LPCN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Lipocine Inc.
    Analyst Report: Lilly(Eli) & CoEli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    20 days agoArgus Research
View more
  • PR Newswire

    Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

    Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place in Boston MA. The results are featured in a late-breaking oral presentation and e-poster by Dr. Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic He

  • PR Newswire

    Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

    Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update.

  • PR Newswire

    Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

    Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to take place in Boston MA, November 10 to 14, 2023.